DEF: BioRestorative Therapies Faces Losses, Seeks Shareholder Votes

BioRestorative Therapies, Inc. announces its Annual Meeting to address director elections, a stock incentive plan increase, auditor ratification, and executive compensation amidst ongoing net losses and declining shareholder returns.

Summary

• The Annual Meeting of Stockholders will be held on September 18, 2025, to elect two Class II directors, approve an amendment to the 2021 Stock Incentive Plan, ratify CBIZ CPAs P.C. as the independent auditor, and hold a non-binding advisory vote on executive compensation.
• The company reported a net loss of $(8,979,381) for fiscal year 2024, an improvement from $(10,417,704) in 2023 and $(13,222,296) in 2022.
• Total Stockholder Return (TSR) on an assumed $100 investment declined from $63.36 in 2022 to $40.09 in 2023, and further to $32.95 in 2024.
• The proposed amendment to the 2021 Stock Incentive Plan seeks to increase authorized shares from 6,850,000 to 9,850,000.
• As of July 31, 2025, 7,978,117 shares of common stock and 1,398,158 shares of Series B preferred stock were outstanding and entitled to vote, though Series B preferred stock is currently not convertible or votable due to beneficial ownership limitations.
• Material weaknesses in internal control over financial reporting were identified for fiscal years ended December 31, 2024 and 2023, related to lack of adherence to policies, risk assessment, effective controls for financial reporting, and accounting for warrants.

Sentiment

Score: 3

Explanation: The company exhibits persistent net losses and a significant decline in Total Stockholder Return over the past three years, indicating poor financial performance. The identified material weaknesses in internal control over financial reporting raise serious concerns about financial integrity and risk management. While the decrease in net loss is a minor positive, the overall financial performance and governance issues are concerning. The increase in stock plan shares could be dilutive if not managed well, but is also for retention.

Positives

• Net loss decreased year-over-year from $(13,222,296) in 2022 to $(8,979,381) in 2024.
• The Board of Directors and its committees (Audit, Nominating, Compensation) are comprised of a majority of independent directors, with all committee members being independent.
• Employment agreements for the CEO and VP of Research and Development extend until March 18, 2026, providing leadership stability.
• The Audit Committee has determined that Patrick F. Williams qualifies as an audit committee financial expert.
• No disagreements were reported with the previous independent registered public accounting firm, Marcum LLP, prior to their resignation due to acquisition.

Negatives

• Total Stockholder Return (TSR) on a $100 investment significantly declined from $63.36 in 2022 to $32.95 in 2024.
• Persistent net losses continue, despite a decreasing trend, indicating ongoing financial challenges.
• Material weaknesses in internal control over financial reporting were identified for fiscal years ended December 31, 2024 and 2023.
• The Nominating Committee did not hold any meetings during the fiscal year ended December 31, 2024.
• One director, David Rosa, attended only approximately 71% of Board and committee meetings during fiscal year 2024.
• A 10% stockholder, Dale Broadrick, filed a Form 4 late during the fiscal year ended December 31, 2024.

Risks

• Material weaknesses in internal control over financial reporting, including lack of adherence to formal policies and procedures, insufficient risk assessment procedures, and inadequate design and implementation of effective controls for financial reporting, disclosures, journal entries, account reconciliations, income taxes, and warrant accounting.
• Broker non-votes may occur on non-routine matters (all proposals except auditor ratification), potentially impacting the outcome of votes if stockholders do not provide specific instructions.
• The Beneficial Ownership Limitation restricts Auctus Fund, LLC's ability to convert Series B preferred stock, exercise warrants, or receive additional shares, which could affect capital structure and investor relations.

Future Outlook

The company's immediate future outlook is centered around its upcoming Annual Meeting on September 18, 2025, where key corporate governance matters, including director elections, an increase in the stock incentive plan, and auditor ratification, will be addressed. The company continues to rely on its equity compensation plan to attract and retain talent, indicating a strategy to incentivize performance and align interests with stockholders.

Management Comments

• Submit proxy or voting instructions as soon as possible, whether or not planning to attend the meeting.
• The Board does not know of any other matters that may be brought before the meeting nor does it foresee or have reason to believe that the proxy holder will have to vote for a substitute or alternate nominee to the Board.
• The Plan plays an important role in efforts to attract and retain employees of outstanding ability and to align the interests of employees with those of the stockholders through increased stock ownership.
• The philosophy and practices have resulted in executive compensation decisions that are appropriate and that have benefited the company over time.

Industry Context

Operating in the healthcare and regenerative medicine sector, the company's reliance on stock incentive plans for talent attraction and retention is a common industry practice, particularly for growth-stage biotech firms. The challenges of persistent net losses and declining shareholder returns are not uncommon in R&D-intensive industries, but the identified material weaknesses in internal controls suggest a need for improved operational and financial oversight to meet industry best practices and investor expectations.

Comparison to Industry Standards

• The company's persistent net losses and declining Total Stockholder Return (TSR) from $63.36 in 2022 to $32.95 in 2024 indicate underperformance compared to successful, growing companies in the medical device and biotech sectors, such as NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), STAAR Surgical Company, or NuVasive, Inc., which typically demonstrate stronger financial trajectories or clear paths to profitability.
• The identified material weaknesses in internal control over financial reporting for 2023 and 2024 fall below the robust financial governance standards expected of publicly traded companies, especially when compared to established firms like St. Jude Medical, Inc. (now part of Abbott) or Allergan (now part of AbbVie), where directors and executives have prior experience.
• The proposed increase in the stock incentive plan shares, while a common tool for talent retention in biotech, needs to be evaluated against the backdrop of the company's declining TSR and ongoing losses to ensure it aligns with shareholder value creation, a key metric for investors in comparable companies.

Corporate Governance

Related Party Transactions

• The company has not formally adopted procedures for the review or approval of related party transactions due to their infrequency; however, the Board of Directors (or a designated committee) reviews such transactions on a case-by-case basis.
• Auctus Fund, LLC, a beneficial owner, holds warrants and Series B preferred stock, which are subject to a 9.99% beneficial ownership limitation, affecting their convertibility and exercisability.

Stakeholder Impact

• Shareholders: Will vote on key corporate governance matters, including director elections, executive compensation, and a significant increase in the stock incentive plan, which could lead to dilution. The declining TSR directly impacts their investment value.
• Employees and Executives: The proposed increase in the 2021 Stock Incentive Plan shares is intended to attract and retain talent through equity awards, directly impacting their compensation and incentives.
• Auditors: The change from Marcum LLP to CBIZ CPAs P.C. due to an acquisition impacts the auditing relationship and continuity of financial oversight.
• Creditors: The ongoing net losses and identified material weaknesses in internal controls could raise concerns about the company's financial health and ability to meet future obligations.

Next Steps

• Hold the Annual Meeting of Stockholders on September 18, 2025.
• Stockholders will vote on the election of two Class II directors.
• Stockholders will vote on the amendment to the 2021 Stock Incentive Plan to increase authorized shares.
• Stockholders will vote on the ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal year 2025.
• Stockholders will hold a non-binding advisory vote on the company's executive compensation.
• The company plans to mail the Notice of Internet Availability of Proxy Materials to stockholders by August 8, 2025.
• Future annual meetings will elect Class I directors in 2027 and Class III directors in 2026, as per the classified Board structure.

Key Dates

Recommendation

The company exhibits persistent net losses and a significant decline in Total Stockholder Return over the past three years, indicating poor financial performance. The identified material weaknesses in internal control over financial reporting raise serious concerns about financial integrity and risk management. While the decrease in net loss is a minor positive, the overall trend and governance issues suggest a high-risk investment with limited near-term upside potential. The proposed increase in the stock incentive plan shares, while for retention, could also lead to further dilution for existing shareholders without clear signs of improved operational performance.

Keywords

BioRestorative Therapies, BRTX, Proxy Statement, Executive Compensation, Stock Incentive Plan, Corporate Governance, Auditor Ratification, Shareholder Meeting, Biotech, Regenerative Medicine, SEC Filing, Internal Controls